VBI Vaccines and SciVac Therapeutics have completed their merger transaction, whereby SciVac acquired VBI. VBI survives the merger as a wholly owned subsidiary of SciVac. Upon completion of the merger, SciVac changed its name to VBI Vaccines Inc. The merger creates a commercial stage company with an approved hepatitis B vaccine, a pipeline of preventative and therapeutic vaccine candidates, and two novel technology platforms. Jeff Baxter, president and chief executive officer, VBI; Davi...